 Zidovudine
"Zidovudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
| Descriptor ID |
D015215
|
| MeSH Number(s) |
D03.383.742.680.705.950 D13.570.230.500.950 D13.570.230.855.950 D13.570.685.705.950
|
| Concept/Terms |
Zidovudine- Zidovudine
- Azidothymidine
- AZT Antiviral
- 3'-Azido-3'-deoxythymidine
- 3' Azido 3' deoxythymidine
- AZT (Antiviral)
- 3'-Azido-2',3'-Dideoxythymidine
- 3' Azido 2',3' Dideoxythymidine
- AZT, Antiviral
- Antiviral AZT
|
Below are MeSH descriptors whose meaning is more general than "Zidovudine".
Below are MeSH descriptors whose meaning is more specific than "Zidovudine".
This graph shows the total number of publications written about "Zidovudine" by people in this website by year, and whether "Zidovudine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 2 | 4 | | 1995 | 1 | 2 | 3 | | 1996 | 1 | 2 | 3 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 0 | 3 | | 2000 | 3 | 0 | 3 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2006 | 2 | 0 | 2 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 2 | 0 | 2 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 3 | 3 | | 2015 | 0 | 2 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Zidovudine" by people in Profiles.
-
Gange WS, Qiao JB, Park PJ, McDonnell JF, Tan Z, Perlman JI, Bu P. Protection of Retinal Function by Nucleoside Reverse Transcriptase Inhibitors Following Retinal Ischemia/Reperfusion Injury. J Ocul Pharmacol Ther. 2021 10; 37(8):485-491.
-
Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. Clin Cancer Res. 2018 07 15; 24(14):3273-3281.
-
Erlandson KM, Fiorillo SP, Cardoso SW, Riviere C, Sanchez J, Hakim J, Kumarasamy N, Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation. AIDS Res Hum Retroviruses. 2017 Sep; 33(9):929-934.
-
Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ, Weinberg A. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015; 10(5):e0127062.
-
Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, Rana A, Kumarasamy N, Hakim J, Campbell TB. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015 May-Jun; 16(3):89-99.
-
Shivakoti R, Gupte N, Yang WT, Mwelase N, Kanyama C, Tang AM, Pillay S, Samaneka W, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Semba RD, Christian P, Campbell TB, Gupta A. Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy. Nutrients. 2014 Nov 13; 6(11):5061-78.
-
Malki S, van der Heijden GW, O'Donnell KA, Martin SL, Bortvin A. A role for retrotransposon LINE-1 in fetal oocyte attrition in mice. Dev Cell. 2014 Jun 09; 29(5):521-533.
-
Erlandson KM, Gudza I, Fiorillo S, Ndemera B, Schooley RT, Gwanzura L, Borok M, Campbell TB. Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe. Int J Infect Dis. 2014 Jul; 24:6-10.
-
Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014; 19(2):141-7.
-
Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 2012 Dec; 22(12):891-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|